SBIR-STTR Award

A Resorbable Hemostat For Laparoscopic Partial Nephrectomy (Lpn)
Award last edited on: 9/20/13

Sponsored Program
SBIR
Awarding Agency
NIH : NIDDK
Total Award Amount
$405,211
Award Phase
1
Solicitation Topic Code
-----

Principal Investigator
Wolff Mayer Kirsch

Company Information

KOAG Medical Inc

1154 W Highland Avenue
Redlands, CA 92373
   (909) 558-7070
   wkirsch@llu.edu
   N/A
Location: Single
Congr. District: 31
County: San Bernardino

Phase I

Contract Number: 1R43DK093275-01A1
Start Date: 8/1/12    Completed: 7/31/13
Phase I year
2012
Phase I Amount
$405,211
There is need for an improved, hemostatic dressing to control renal hemorrhage associated with new nephron-sparing endourologic procedures such as laparoscopic partial nephrectomy (LPN). Our surgical laboratory and small business (KOAG) has developed a cost-effective, microfibrillar chitosan hemostat approved by the FDA for topical use. Chitosan is sourced from chitin, earth's second most natural abundant biopolymer and seafood industry waste product. Chitosan is a biodegradable polyglucosamine polymer that requires depyrogenation before implantation in humans. Our goal is to meet the need for a cost-effective endourologic resorbable hemostat by innovative nitrogen plasma detoxification of microfibrillar chitosan. Our Phase I SBIR study is designed to optimize a non-thermal nitrogen plasma depyrogenation method and simultaneously increase mucoadhesivity and hemostatic effectiveness by surface nitrogenation. A safety and efficacy study of the biocompatibility and hemostaticeffectiveness of depyrogenated-nitrogenated microfibrillar chitosan will be conducted in the porcine LPN model as a Phase I study with proof of safety and efficacy. A head-to-head comparison of our product to other available LPN hemostats will be conducted as a Phase II study.

Public Health Relevance:
Development of an economical, resorbable hemostat that can be applied endoscopically will facilitate advances in minimal invasive nephron sparing surgery. An innovative detoxification procedure - lowtemperature nitrogen plasma - will be used to detoxify microfibrillar chitosan for implantation.

Thesaurus Terms:
Advanced Practice Nurse;Base;Biomaterial Compatibility;Biopolymers;Businesses;Chitin;Chitosan;Clinical;Cold Temperature;Cost Effective;Cost Effectiveness;Design;Drug Metabolic Detoxication;Economic Development;Effectiveness;Extravasation;Family Suidae;Fda Approved;Feasibility Studies;Goals;Head-To-Head Comparison;Hemorrhage;Hemostatic Agents;Hemostatic Function;Human;Implant;Implantation;Improved;Industry;Innovation;Kidney;Laboratories;Legal Patent;Meetings;Methods;Modeling;Nephrectomy;Nephrons;Nitrogen;Novel;Operative Surgical Procedures;Performance;Phase;Phase 1 Study;Phase 2 Study;Plasma;Polymers;Procedures;Safety;Seafood;Small Business Innovation Research Grant;Sterile Coverings;Surface;Technology;Time;Urine;Warm Ischemia;Waste Products

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
----
Phase II Amount
----